# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Morgan Stanley analyst Patrick Wood maintains DexCom (NASDAQ:DXCM) with a Equal-Weight and lowers the price target from $132...
Stifel analyst Mathew Blackman maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $145 to $132.
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will s...
Dexcom Inc. has enabled direct Apple Watch connectivity for its G7 glucose monitor, allowing users to access real-time glucose ...